TNDM:NSD-Tandem Diabetes Care Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 125.35

Change

0.00 (0.00)%

Market Cap

USD 7.90B

Volume

1.10M

Avg Analyst Target

USD 124.33 (-0.81%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-16 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology Inc

N/A

USD46.66B 67.21 49.74
PODD Insulet Corporation

N/A

USD20.70B 2,208.27 247.98
ABMD Abiomed Inc

N/A

USD15.95B 103.89 50.66
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

N/A

USD11.66B 49.76 25.84
SWAV ShockWave Medical Inc

N/A

USD6.92B N/A N/A
INMD InMode Ltd

N/A

USD6.51B 56.98 39.02
IART Integra LifeSciences Holdings ..

N/A

USD5.72B 28.04 18.47
LIVN LivaNova PLC

N/A

USD4.46B 77.40 N/A
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67

ETFs Containing TNDM

Symbol Name Weight Mer Price(Change) Market Cap
JKK iShares Morningstar Small.. 0.00 % 0.06 %

N/A

USD0.86B
SLIM The Obesity ETF 0.00 % 0.35 %

N/A

USD0.01B
EDOC Global X Telemedicine & D.. 0.00 % 0.68 %

N/A

N/A
ISCG iShares Morningstar Small.. 0.00 % 0.06 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 31.01% 66% D 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.01% 66% D 75% C
Trailing 12 Months  
Capital Gain 5.57% 39% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.57% 39% F 33% F
Trailing 5 Years  
Capital Gain 89.92% 73% C 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 89.92% 73% C 64% D
Average Annual (5 Year Horizon)  
Capital Gain 249.83% 97% A+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 249.83% 97% A+ 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 467.50% 5% F 4% F
Risk Adjusted Return 53.44% 74% C 71% C-
Market Capitalization 7.90B 96% A 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1,216.99 8% F 1% F
Price/Book Ratio 23.37 7% F 5% F
Price / Cash Flow Ratio 320.27 2% F 2% F
EV/EBITDA 251.84 8% F 4% F
Management Effectiveness  
Return on Equity 2.14% 82% B- 54% F
Return on Invested Capital -9.00% 62% D- 35% F
Return on Assets 1.76% 80% B- 62% D-
Debt to Equity Ratio 55.41% 45% F 36% F
Technical Ratios  
Short Ratio 4.03 50% F 39% F
Short Percent 7.26% 23% F 25% F
Beta 0.25 88% B+ 91% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.